Medikamentenpumpen und tiefe Hirnstimulation in der Parkinsontherapie

Zusammenfassung

In den fortgeschrittenen Krankheitsstadien des idiopathischen Parkinsonsyndroms ist häufig keine ausreichende Symptomkontrolle unter oraler Medikation möglich. Insbesondere bei schweren Wirkfluktuationen stellen invasive Therapieverfahren eine erfolgversprechende Behandlungsoption dar. Die vorliegende Übersichtsarbeit befasst sich mit der Differenzialindikation für den Einsatz der tiefen Hirnstimulation und der Behandlungsverfahren mit Medikamentenpumpen, zu denen die intrajejunale Gabe von Levodopa und die subkutane Infusion von Apomorphin zählen.

Abstract

Oral pharmacotherapy is often insufficient to obtain stable control of motor symptoms in advanced stages of Parkinson's disease. Invasive therapies can be a promising option for the treatment of severe response fluctuations. In the present review, the differential indication for invasive treatments, comprising deep brain stimulation, intrajejunal delivery of levodopa and subcutaneous infusion of apomorphine will be discussed.

Schlüsselwörter

Parkinson - tiefe Hirnstimulation - Apomorphin - Duodopa

Keywords

Parkinson's disease - deep brain stimulation - apomorphine - duodopa

Literatur

• 1 Deuschl G, Schade-Brittinger C, Krack P. A randomized trial of deep-brain stimulation for Parkinson's disease.  N Engl J Med. 2006;  355 896-908
• 2 Weaver F M, Follett K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial.  JAMA. 2009;  301 63-73
• 3 Diener H, Putzki N, Berlit P. Leitlinien für die Diagnostik und Therapie in der Neurologie.. 4. überarbeitete Auflage ed. Stuttgart: Georg Thieme Verlag; 2008
• 4 Saint-Cyr J A, Trepanier L L, Kumar R et al. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease.  Brain. 2000;  123 2091-2108
• 5 Derost P P, Ouchchane L, Morand D et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?.  Neurology. 2007;  68 1345-1355
• 6 Goetz C G, Poewe W, Rascol O et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.  Mov Disord. 2005;  20 523-539
• 7 Witt K, Daniels C, Reiff J et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study.  Lancet Neurol. 2008;  7 605-614
• 8 Aybek S, Gronchi-Perrin A, Berney A et al. Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson's disease.  Mov Disord. 2007;  22 974-981
• 9 Garcia Ruiz P J, Sesar I A, Ares P B et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.  Mov Disord. 2008;  23 1130-1136
• 10 Krack P, Poepping M, Weinert D et al. Thalamic, pallidal, or subthalamic surgery for Parkinson's disease?.  J Neurol. 2000;  247 (S 02) II122-II134
• 11 Trepanier L L, Kumar R, Lozano A M et al. Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease.  Brain Cogn. 2000;  42 324-347
• 12 de Gaspari D, Siri C, Landi A et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.  J Neurol Neurosurg Psychiatry. 2006;  77 450-453
• 13 Ellis C, Lemmens G, Parkes J D et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment.  Parkinsonism and Related Disorders. 1997;  3 103-107
• 14 van Laar T, Postma A G, Drent M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.  Parkinsonism Relat Disord. 2010;  16 71-72
• 15 Manson A J, Turner K, Lees A J. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.  Mov Disord. 2002;  17 1235-1241
• 16 Voges J, Koulousakis A, Sturm V. Deep brain stimulation for Parkinson's disease.  Acta Neurochir. 2007;  (S 97) 171-184
• 17 Hamani C, Neimat J, Lozano A M. Deep brain stimulation for the treatment of Parkinson's disease.  J Neural Transm. 2006;  Suppl 393-399
• 18 Clarke C E, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.  Parkinsonism Relat Disord. 2009;  15 728-741
• 19 Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.  Mov Disord. 2009;  24 993-1000